Comparative Pharmacology
Head-to-head clinical analysis: BETAXON versus BETOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXON versus BETOPTIC.
BETAXON vs BETOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
Instill 1 drop of 0.5% solution in the affected eye(s) twice daily.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Terminal elimination half-life: 4–5 hours. With topical ophthalmic administration, systemic absorption is minimal, so half-life refers to IV data.
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Renal (fecal <5%). 60% as unchanged drug, 40% as inactive metabolites.
Category C
Category C
Beta-Blocker
Beta-Blocker